THERAVANCE INC - CORPORATE OBLIG

CUSIP: 88338TAB0

Q4 2017 13F Holders as of 31 Dec 2017

Type / Class
Debt / CORPORATE OBLIG
Market price (% of par)
99.11%
Total 13F principal
$184,115,604
Principal change
-$18,903,088
Total reported market value
$183,653,201
Number of holders
35
Value change
-$17,575,315
Number of buys
14
Number of sells
12

Quarterly Holders Quick Answers

What is CUSIP 88338TAB0?
CUSIP 88338TAB0 identifies 88338TAB0 - THERAVANCE INC - CORPORATE OBLIG in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of THERAVANCE INC - CORPORATE OBLIG as of Q4 2017

As of 31 Dec 2017, THERAVANCE INC - CORPORATE OBLIG was held by 35 institutional bondholders reporting positions in Form 13F filings. These institutions reported holding $184,115,604 in principal (par value) of the bond. The largest 10 bondholders included Linden Advisors LP, CNH PARTNERS LLC, OAKTREE CAPITAL MANAGEMENT LP, CALAMOS ADVISORS LLC, LAZARD ASSET MANAGEMENT LLC, AMUNDI PIONEER ASSET MANAGEMENT INC, Castle Creek Arbitrage, LLC, AMERIPRISE FINANCIAL INC, SSI INVESTMENT MANAGEMENT INC, and ADVENT CAPITAL MANAGEMENT /DE/. This page lists 35 institutional bondholders reporting positions for the Q4 2017 filing period.
Investor Option Weight % Change % Value $ * Price (% of par) Principal Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.